CTOs on the Move

B-One

www.b1.co

 
A few individuals with decades of experience in the U.S. orthopedic industry,came together in 2015 because they saw the need for a first-class company that was Agile,creative and innovative in a global market subject to advancing technologies and changing policies.They had seen the successes of the large companies, but they had witnessed compromises that had to be made.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.b1.co
  • 636 Shelby Street 4th Floor
    Bristol, TN USA 37620
  • Phone: N/A

Executives

Name Title Contact Details

Funding

B-One raised $14M on 03/03/2020

Similar Companies

EvoEndo

EvoEndo develops systems that enable unsedated endoscopic procedures through a combination of sterile single-use, multi-specialty flexible endoscopes; VR-based patient distraction; and a comprehensive software integration platform.

Lasergen

Lasergen is an emerging biotechnology company focused on commercializing novel technologies for DNA sequencing. Our expertise in nucleotide chemistry and next-generation sequencing has led to a number of key discoveries resulting in both game-changing sequencing chemistry (Lightning Terminators™) and a more accurate sequencing platform. While focusing on the development of current cutting-edge technology, our continued drive for innovation and extensive sequencing knowledge allows us to rapidly evolve and keep pace with fast-changing advances in the sequencing industry.

Mededge Inc

Mededge Inc is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Newmark Inc

Newmark is a Cheshire, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RenalGuard Solutions

Headquartered in Milford, Massachusetts, RenalGuard Solutions, Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard`s effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA. The RenalGuard System™ consists of a closed loop, software-controlled console and single-use sets that physicians and nurses use for automated matched fluid replacement to minimize over- or under-hydration of patients during medical procedures where creating and maintaining high urine outputs is beneficial.